DuraSorb’s timeline of tissue ingrowth and resorption 2*
*Pre-clinical results may not be indicative of clinical results
SIA was acquired by Integra LifeSciences in December 2022. Read the press release here.
A fully-resorbable knitted mesh engineered to address limitations in current soft tissue support options. The device’s proprietary design balances strength and resorption while maintaining softness, compliance, and drapeability.1,2*
*Pre-clinical results may not be indicative of clinical results.
DuraSorb is a bioresorbable mesh composed of polydioxanone, a PDO suture material used clinically for over 40 years.3
*Pre-clinical results may not be indicative of clinical results.
DuraSorb® Monofilament Mesh is intended for use in reinforcement of soft tissue where weakness exists.
DuraSorb® is intended for use by licensed medical professionals.
Contraindications
Precautions
Warnings
ADVERSE REACTIONS
Possible adverse reactions with DuraSorb® are those typically associated with any implantable mesh, including, but not limited to, infection, re-operation for mesh removal, inflammation, extrusion, erosion, adhesion, fistula formation, seroma formation, hematoma, mechanical mesh failure, dehiscence, necrosis, and recurrence of the hernia or tissue defect.
DuraSorb and the Integra logo are registered trademarks of Integra LifeSciences Corporation or its subsidiaries in the United States and/or other countries.
© 2024 Integra LifeSciences Corporation. All rights reserved. 4227209-1-EN
Merritt leads customer experience and sales analytics at SIA following two decades thriving in roles that allow her to ethically serve companies and key corporate stakeholders. Merritt manages customer-facing sales operations and is working to establish best-in-class loyalty, customer engagement and internal reporting to drive business growth. With roles at Sientra (NYSE: SIEN), CBRE, Inc. and Lord Abbett & Co., LLC, Merritt has thrived within heavily-regulated fields while continuing to drive customer acquisition, retention, and revenue generation.
Dr. Sisco is Chief of Plastic Surgery at NorthShore University HealthSystem in Evanston, IL and Clinical Associate Professor of Surgery at University of Chicago. His practice focuses on breast reconstruction and aesthetic surgery of the face and body. As an avid researcher, he has produced over 40 peer-reviewed articles and presentations, and performed pioneering laboratory research on scar formation and healing.
Dr. Karp is a Professor of Plastic Surgery at NYU School of Medicine, Vice Chair of Clinical Operations at Hansjörg Wyss Department of Plastic Surgery, and Chief of Plastic Surgery and Director of the Breast Service at NYU-Tisch Hospital. He specializes in breast and body contouring plastic surgery and has extensive experience in all areas of breast surgery. He has authored over 10 chapters and 100 peer-reviewed papers, with particular focus on 3D scanning to plan and follow plastic surgery of the breast, and internal support for aesthetic and reconstructive breast surgery.
John is a serial entrepreneur who co-founded three medical device companies and brings 15 years of operating CFO experience to SIA. John was most recently CFO/Co-Founder of Attune Medical, manufacturer of a novel patient temperature management device with scaling global sales. Prior to that, John co-founded Farapulse (formerly known as Iowa Approach), a company pioneering a disruptive atrial fibrillation ablation technology funded by Boston Scientific (NYSE: BSX) and several venture capitalists. Previously, John was CFO/Co-Founder of Corvida Medical, a device he invented and commercialized to enable safer delivery of chemotherapy medications. John holds multiple patents and received a Bachelor’s Degree in Finance from University of Iowa.